Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion

admin by admin
October 23, 2024
in Stock
0
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

(Reuters) – Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday.

As part of the deal, the U.S. drugmaker paid $30 million upfront. Modifi is also eligible to receive potential milestone payments of up to $1.3 billion in exchange for a new class of therapies, KL-50 — being developed against difficult-to-treat brain tumors, including glioblastomas.

New Haven, Connecticut-based Modifi is a pre-clinical stage company, which develops cancer therapies that aim to selectively kill cancer cells by modifying cancer DNA.

Modifi has raised $10.7 million to date in seed funding and is backed by investors including American Cancer Society’s investment arm, BrightEdge.

Merck has been in pursuit of eligible candidates that could potentially make up for a loss of revenue from its aging blockbuster cancer immunotherapy, Keytruda, which is set to lose its patent protection by the end of the decade.

Last year, the company struck a $5.5 billion deal with Japan’s Daiichi Sankyo to jointly develop three of its targeted cancer therapies, known as antibody drug conjugates, which work like “guided missiles” against tumor cells while sparing healthy ones.

This post appeared first on investing.com

Previous Post

Earnings call: Cadence Bank reports steady Q3 growth, eyes future momentum

Next Post

McDonald’s E. coli crisis: the bacteria has a history of taking down restaurant sales and shares

admin

admin

Next Post
McDonald’s E. coli crisis: the bacteria has a history of taking down restaurant sales and shares

McDonald’s E. coli crisis: the bacteria has a history of taking down restaurant sales and shares

Trending News

What’s next for Paramount stock after FCC’s approval for Skydance merger?

What’s next for Paramount stock after FCC’s approval for Skydance merger?

July 26, 2025
Mastercard offers mid-term guidance, shares rise

Mastercard offers mid-term guidance, shares rise

November 13, 2024
The big tech sell-off: are the ‘Magnificent 7’ stocks overvalued or oversold?

The big tech sell-off: are the ‘Magnificent 7’ stocks overvalued or oversold?

March 19, 2025
Subscribe to Insightful Word


    Recent News

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    August 28, 2025
    SentinelOne stock price forecast ahead of earnings: buy or sell?

    SentinelOne stock price forecast ahead of earnings: buy or sell?

    August 28, 2025
    Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    August 28, 2025
    Urban Outfitters stock slides 4% despite strong quarter on cautious outlook

    Urban Outfitters stock slides 4% despite strong quarter on cautious outlook

    August 28, 2025

    Recent News

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    August 28, 2025
    SentinelOne stock price forecast ahead of earnings: buy or sell?

    SentinelOne stock price forecast ahead of earnings: buy or sell?

    August 28, 2025

    Latest News

    • Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in
    • SentinelOne stock price forecast ahead of earnings: buy or sell?
    • Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.